Physician profile
Maria Steele
NPI 1083012850
$4,096.72
in general payments reported to CMS, 2019-2025
23 companies · $21.58 in 2025
The $21.58 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $719 · 2022: $1,544 · 2023: $1,139 · 2024: $673 · 2025: $21.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $790.82 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $451.67 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $350.64 | 2021-2024 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $262.83 | 2021-2023 | |
| Bausch Health US, LLC | $244.10 | 2021-2024 | Aplenzin, Wellbutrin |
| Almatica Pharma LLC | $236.97 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $228.07 | 2021-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $218.27 | 2021-2023 | Ingrezza |
| Corium, LLC | $187.52 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $175.97 | 2022-2024 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $146.05 | 2021-2022 | |
| Lundbeck LLC | $135.26 | 2021-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $132.70 | 2021-2022 | |
| Indivior INC. | $110.39 | 2021-2024 | Sublocade |
| Supernus Pharmaceuticals, INC. | $85.10 | 2022-2023 | Qelbree |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $71.13 | 2023-2024 | Wakix |
| Tris Pharma INC | $64.22 | 2022-2023 | Dyanavel Xr |
| Ironshore Pharmaceuticals INC. | $46.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $45.37 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $41.63 | 2024 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $31.73 | 2022-2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $21.55 | 2021 | |
| Neos Therapeutics, LP | $18.38 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Steele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.